These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 18574662)

  • 1. Susceptibility of clinical isolates of Pseudomonas aeruginosa in the Northern Kyushu district of Japan to carbapenem antibiotics, determined by an integrated concentration method: evaluation of the method based on Monte Carlo simulation.
    Nagasawa Z; Kusaba K; Aoki Y
    J Infect Chemother; 2008 Jun; 14(3):238-43. PubMed ID: 18574662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory].
    Sumitani Y; Kobayashi Y
    Jpn J Antibiot; 2007 Dec; 60(6):394-403. PubMed ID: 18447209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the pharmacodynamic profile of intravenous antibiotics against prevalent Gram-negative organisms collected in Colombia.
    Villegas MV; Briceno DF; Ruiz SJ; Furtado GH; Nicolau DP
    Braz J Infect Dis; 2011; 15(5):413-9. PubMed ID: 22230846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of dosing designs of carbapenems for severe respiratory infection using Monte Carlo simulation.
    Watanabe A; Fujimura S; Kikuchi T; Gomi K; Fuse K; Nukiwa T
    J Infect Chemother; 2007 Oct; 13(5):332-40. PubMed ID: 17982723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. When pharmacodynamics trump costs: an antimicrobial stewardship program's approach to selecting optimal antimicrobial agents.
    Goff DA; Nicolau DP
    Clin Ther; 2013 Jun; 35(6):766-71. PubMed ID: 23795574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pseudomonas aeruginosa is not just in the intensive care unit any more: implications for empirical therapy.
    Eagye KJ; Banevicius MA; Nicolau DP
    Crit Care Med; 2012 Apr; 40(4):1329-32. PubMed ID: 22425824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibacterial activity of carbapenems against clinical isolates of respiratory bacterial pathogens in the northeastern region of Japan in 2007.
    Gomi K; Fujimura S; Fuse K; Takane H; Nakano Y; Kariya Y; Kikuchi T; Kurokawa I; Tokue Y; Watanabe A
    J Infect Chemother; 2011 Apr; 17(2):200-6. PubMed ID: 20839026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures.
    Kim A; Banevicius MA; Nicolau DP
    Antimicrob Agents Chemother; 2008 Jul; 52(7):2497-502. PubMed ID: 18458125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing intravenous fosfomycin dosing in combination with carbapenems for treatment of Pseudomonas aeruginosa infections in critically ill patients based on pharmacokinetic/pharmacodynamic (PK/PD) simulation.
    Asuphon O; Montakantikul P; Houngsaitong J; Kiratisin P; Sonthisombat P
    Int J Infect Dis; 2016 Sep; 50():23-9. PubMed ID: 27418581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating biapenem dosage regimens in intensive care unit patients with Pseudomonas aeruginosa infections: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation.
    Hang Y; Chen Y; Xue L; Sun S; Liu L; Gao J; Xie C; Zhang X; Zhu J; Jin J; Miao L
    Int J Antimicrob Agents; 2018 Mar; 51(3):484-487. PubMed ID: 28709989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Susceptibility of Pseudomonas aeruginosa clinical isolates in Japan to doripenem and other antipseudomonal agents.
    Fujimura T; Anan N; Sugimori G; Watanabe T; Jinushi Y; Yoshida I; Yamano Y
    Int J Antimicrob Agents; 2009 Dec; 34(6):523-8. PubMed ID: 19748767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential.
    Mushtaq S; Ge Y; Livermore DM
    Antimicrob Agents Chemother; 2004 Aug; 48(8):3086-92. PubMed ID: 15273124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis.
    Kuti JL; Nightingale CH; Quintiliani R; Nicolau D
    Diagn Microbiol Infect Dis; 2002 Sep; 44(1):51-7. PubMed ID: 12376031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Occurrence of PER-1 producing clinical isolates of Pseudomonas aeruginosa in Japan and their susceptibility to doripenem.
    Yamano Y; Nishikawa T; Fujimura T; Yutsudou T; Tsuji M; Miwa H
    J Antibiot (Tokyo); 2006 Dec; 59(12):791-6. PubMed ID: 17323646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem.
    Riera E; Cabot G; Mulet X; García-Castillo M; del Campo R; Juan C; Cantón R; Oliver A
    J Antimicrob Chemother; 2011 Sep; 66(9):2022-7. PubMed ID: 21653605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
    Moczygemba LR; Frei CR; Burgess DS
    Clin Ther; 2004 Nov; 26(11):1800-7. PubMed ID: 15639692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experimental verification of the efficacy of optimized two-step infusion therapy with meropenem using an in vitro pharmacodynamic model and Monte Carlo simulation.
    Eguchi K; Kanazawa K; Shimizudani T; Kanemitsu K; Kaku M
    J Infect Chemother; 2010 Feb; 16(1):1-9. PubMed ID: 20072800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [In vitro activity of doripenem and other carbapenems against Pseudomonas aeruginosa].
    Nicola F; García Ramírez D; Arduino S; Di Chiara M; Smayevsky J
    Rev Argent Microbiol; 2010; 42(3):193-8. PubMed ID: 21186673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation by Monte Carlo simulation of levofloxacin dosing for complicated urinary tract infections caused by Escherichia coli or Pseudomonas aeruginosa.
    Deguchi T; Seike K; Yasuda M; Matsumoto T
    J Infect Chemother; 2011 Oct; 17(5):726-30. PubMed ID: 21409530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delayed resistance selection for doripenem when passaging Pseudomonas aeruginosa isolates with doripenem plus an aminoglycoside.
    Huynh HK; Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 2006 Jul; 55(3):241-3. PubMed ID: 16725297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.